NCT01264211已完成2 期
A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Percentage of patients with ACR20 response criteria
研究概览
简要总结
To evaluate the efficacy of Diacerein 100 mg daily versus placebo in reducing rheumatoid arthritis symptoms, when added to stable oral MTX therapy in patients with active early RA.
To evaluate the safety of Diacerein 100 mg daily when administrated in combination with oral MTX therapy in those patients for up to 24 weeks
To investigate a potential persistent effect, 4 weeks after Diacerein treatment is stopped (carry-over effect)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged between 18 and 65 years;
- •Active RA of ≥ 3 months duration but < 2 years, diagnosed according to the American College of Rheumatology (ACR) 1987 revised criteria for RA;
- •RA global functional status class I-III;
- •Treatment on an outpatient basis;
- •Treatment with MTX for a minimum of 12 weeks, with stable weekly dose (10-20 mg) for at least 4 weeks before randomisation;
- •Insufficient response to treatment with MTX, with disease activity score DAS28 > 4.0 at the time of screening and randomisation; the DAS28 must not change significantly from screening to baseline visit (change < 0.6);
- •Tender joint count (TJC) ≥ 6 (68 joint count) and swollen joint count (SJC) ≥ 6 (66 joint count) at screening and randomisation;
- •Screening ESR ≥ 28 mm/h;
- •Evidence of adequate contraceptive methods in women of childbearing potential. Female patients of childbearing potential are those who are not surgically sterile or post-menopausal. Adequate contraceptive methods are hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the entire duration of the study;
- •Agreement not to drink alcohol for the duration of the study;
- •Ability and agreement to comply with the requirements of the study protocol;
- •Having given written informed consent to participate in the study.
排除标准
- •History of active inflammatory arthritis other than RA;
- •Any uncontrolled medical condition such as diabetes mellitus, asthma, cardiopulmonary disease, congestive heart failure, neurological disease, etc.;
- •Alcohol abuse, defined as the consumption of more than one glass of beer or wine in a day;
- •Moderate or severe liver disease (cirrhosis, hepatitis, liver insufficiency);
- •Blood anomalies (significant cytopenia);
- •History of, or currently active primary or secondary immunodeficiency;
- •Chronic hepatitis B (HBsAg positive or HBcAb positive with HBV DNA load ≥ 400 copies/ml) or hepatitis C (anti-HCV positive);
- •Current known active, or history of, recurrent bacterial, viral, fungal, mycobacterial or other infections, or any infection requiring hospitalisation or treatment with i.v. antibiotics within 4 weeks prior to randomisation or oral antibiotics within 2 weeks prior to randomisation;
- •Treatment with biologic DMARDs such as TNF antagonists, IL 1 receptor antagonists, IL 6 receptor antagonists, CTLA4Ig within 12 weeks prior to randomisation, and rituximab within 24 weeks prior to randomisation;
- •Treatment with non-biologic DMARDs such as chloroquine, hydroxychloroquine, penicillamine, sulfasalazine within 4 weeks prior to randomisation, leflunomide, parenteral gold, oral gold within 8 weeks prior to randomisation, azathioprine and ciclosporin within 12 weeks prior to randomisation;
- •Treatment with intra-articular injection of a depocorticosteroid within 8 weeks prior to randomisation;
- •Treatment with NSAID or oral corticosteroids, unless the patient has been on a stable dose for at least 4 weeks before randomisation (maximal allowed daily dose of oral corticosteroid equivalent to prednisone 10 mg);
- •Physical therapy and alternative therapies, unless the patient has received them regularly for at least 4 weeks before randomisation;
- •Initiation of chronic treatment with antihistaminics, antidepressants or tranquilisers, within less than 12 weeks before randomisation.
研究组 & 干预措施
Diacerein
Experimental
干预措施: Diacerein (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of patients with ACR20 response criteria
时间窗: 24 weeks
次要结局
- Percentage of patients achieving a moderate response according to EULAR response criteria (changes in DAS28 score)(24 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Study Design of the Diacerein in Patients With Covid-19COVID-19NCT05226754University of Campinas, Brazil40
已完成
2 期
A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT00713544AstraZeneca373
终止
2 期
Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid ArthritisArthritis, RheumatoidNCT02214888Boehringer Ingelheim170
已完成
2 期
A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)Rheumatoid ArthritisNCT00132769Merck Sharp & Dohme LLC106
Unknown
1 期
Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEADiabetic Peripheral Neuropathic PainNCT05766969Pure Green Pharmaceuticals Inc.52